Top

Published in:

Open Access 01-03-2019 | Commentary

Clinical Goals and Barriers to Effective Psoriasis Care

Authors: Bruce E. Strober, Joelle M. van der Walt, April W. Armstrong, Marc Bourcier, Andre V. E. Carvalho, Edgardo Chouela, Arnon D. Cohen, Claudia de la Cruz, Charles N. Ellis, Andrew Y. Finlay, Alice B. Gottlieb, Johann E. Gudjonsson, Lars Iversen, C. Elise Kleyn, Craig L. Leonardi, Charles W. Lynde, Caitriona Ryan, Colin T. Theng, Fernando Valenzuela, Ronald Vender, Jashin J. Wu, Helen S. Young, Alexa B. Kimball

Published in: Dermatology and Therapy | Issue 1/2019

Abstract

Engaging global key opinion leaders, the International Psoriasis Council (IPC) held a day-long roundtable discussion with the primary purpose to discuss the treatment goals of psoriasis patients and worldwide barriers to optimal care. Setting clear expectations might ultimately encourage undertreated psoriasis patients to seek care in an era in which great gains in therapeutic efficacy have been achieved. Here, we discuss the option for early treatment of all categories of psoriasis to alleviate disease impact while emphasizing the need for more focused attention for psoriasis patients with mild and moderate forms of this autoimmune disease. In addition, we encourage policy changes to keep pace with the innovative therapies and clinical science and highlight the demand for greater understanding of treatment barriers in resource-poor countries.

Boehncke WH, Boehncke S. More than skin-deep: the many dimensions of the psoriatic disease. Swiss Med Wkly. 2014;144:w13968. https://doi.org/10.4414/smw.2014.13968.CrossRefPubMed

Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149(10):1180–5. https://doi.org/10.1001/jamadermatol.2013.5264.CrossRefPubMed

van de Kerkhof PC, Reich K, Kavanaugh A, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatol Venereol. 2015;29(10):2002–10. https://doi.org/10.1111/jdv.13150.CrossRefPubMedPubMedCentral

Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87–97. https://doi.org/10.1007/s40257-015-0169-x.CrossRefPubMed

Armstrong AW, Koning JW, Rowse S, Tan H, Mamolo C, Kaur M. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data. Dermatol Ther (Heidelb). 2016. https://doi.org/10.1007/s13555-016-0153-2.CrossRefPubMedPubMedCentral

World Health Organization. World Health Organization global report on psoriasis. Geneva: World Health Association; 2016.

Armstrong A, Jarvis S, Boehncke WH, et al. Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. J Eur Acad Dermatol Venereol. 2018;32(12):2200–2207. https://doi.org/10.1111/jdv.15065.CrossRefPubMed

Florek AG, Wang CJ, Armstrong AW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res. 2018;310(4):271–319. https://doi.org/10.1007/s00403-018-1808-x.CrossRefPubMed

Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician’s global assessment. J Am Acad Dermatol. 2004;51(4):563–9. https://doi.org/10.1016/j.jaad.2004.04.012.CrossRefPubMed

10.

Finlay AY, Khan GK. Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.CrossRef

11.

Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol. 2014;70(5):871–81. https://doi.org/10.1016/j.jaad.2013.12.018.CrossRefPubMed

12.

Ryan C, Menter A. Discordance between physician assessment of psoriasis and patient self-assessment: the importance of itch. Br J Dermatol. 2016;175(1):19–20. https://doi.org/10.1111/bjd.14672.CrossRefPubMed

13.

Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes. 2009;7:62. https://doi.org/10.1186/1477-7525-7-62.CrossRefPubMedPubMedCentral

14.

Szepietowski JC, Reich A. Itch in psoriasis management. Curr Probl Dermatol. 2016;50:102–10. https://doi.org/10.1159/000446050.CrossRefPubMed

15.

Kimball AB, Luger T, Gottlieb A, et al. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: results from 3 phase III psoriasis clinical trials. J Am Acad Dermatol. 2016. https://doi.org/10.1016/j.jaad.2016.07.034.CrossRefPubMed

16.

Leonardi CL, Blauvelt A, Sofen HL, et al. Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. J Eur Acad Dermatol Venereol. 2017. https://doi.org/10.1111/jdv.14211.CrossRefPubMed

17.

Feldman SR, Thaci D, Gooderham M, et al. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016. https://doi.org/10.1016/j.jaad.2016.07.040.CrossRefPubMed

18.

Sobell JM, Foley P, Toth D, et al. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol. 2016;96(4):514–20. https://doi.org/10.2340/00015555-2360.CrossRefPubMed

19.

Mrowietz U, Chouela EN, Mallbris L, et al. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study. J Eur Acad Dermatol Venereol. 2015;29(6):1114–20. https://doi.org/10.1111/jdv.12761.CrossRefPubMed

20.

Stull C, Grossman S, Yosipovitch G. Current and emerging therapies for itch management in psoriasis. Am J Clin Dermatol. 2016;17(6):617–24. https://doi.org/10.1007/s40257-016-0213-5.CrossRefPubMed

21.

Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat. 2015;26(3):235–9. https://doi.org/10.3109/09546634.2014.943687.CrossRefPubMed

22.

Anstey A, McAteer H, Kamath N, Percival F. Extending psychosocial assessment of patients with psoriasis in the UK, using a self-rateds, web-based survey. Clin Exp Dermatol. 2012;37(7):735–40. https://doi.org/10.1111/j.1365-2230.2012.04457.x.CrossRefPubMed

23.

Eghlileb AM, Davies EE, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol. 2007;156(6):1245–50. https://doi.org/10.1111/j.1365-2133.2007.07881.x.CrossRefPubMed

24.

Sampogna F, Abeni D, Gieler U, et al. Impairment of sexual life in 3,485 dermatological outpatients from a multicentre study in 13 European countries. Acta Derm Venereol. 2017;97(4):478–82. https://doi.org/10.2340/00015555-2561.CrossRefPubMed

25.

Ryan C, Sadlier M, De Vol E, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015;72(6):978–83. https://doi.org/10.1016/j.jaad.2015.02.1127.CrossRefPubMed

26.

Strober B, Papp KA, Lebwohl M, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016. https://doi.org/10.1016/j.jaad.2016.03.026.CrossRefPubMed

27.

Lebwohl M, Swensen AR, Nyirady J, Kim E, Gwaltney CJ, Strober BE. The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument. Int J Dermatol. 2014;53(6):714–22. https://doi.org/10.1111/j.1365-4632.2012.05798.x.CrossRefPubMed

28.

Safikhani S, Sundaram M, Bao Y, Mulani P, Revicki DA. Qualitative assessment of the content validity of the dermatology life quality index in patients with moderate to severe psoriasis. J Dermatol Treat. 2013;24(1):50–9. https://doi.org/10.3109/09546634.2011.631980.CrossRef

29.

Loo WJ, Diba V, Chawla M, Finlay AY. Dermatology Life Quality Index: influence of an illustrated version. Br J Dermatol. 2003;148(2):279–84.CrossRef

30.

Kitchen H, Cordingley L, Young H, Griffiths CE, Bundy C. Patient-reported outcome measures in psoriasis: the good, the bad and the missing! Br J Dermatol. 2015;172(5):1210–21. https://doi.org/10.1111/bjd.13691.CrossRefPubMed

31.

Ali FM, Cueva AC, Vyas J, et al. A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. Br J Dermatol. 2017;176(3):577–93. https://doi.org/10.1111/bjd.14788.CrossRefPubMed

32.

Greb JE, Merola J, Garg A, et al. The psoriatic disease payer advisory panel. J Drugs Dermatol. 2016;15(5):641–4.PubMed

33.

Merola JF, Armstrong AW, Saraiya A, et al. International dermatology outcome measures initiative as applied to psoriatic disease outcomes: an update. J Rheumatol. 2016;43(5):959–60. https://doi.org/10.3899/jrheum.160114.CrossRefPubMed

34.

Callis Duffin KMJ, Christensen R, Latella J, Garg A, Gottlieb AB, Armstrong AW. Identifying a core domain set to assess psoriasis in clinical trials: a combined delphi consensus survey from the international dermatology outcome measures initiative. JAMA Dermatol.2018;154(10):1137–44. https://doi.org/10.1001/jamadermatol.2018.1165

35.

Perez-Chada LM Singh S, Callis-Duffin K, et al.. International Dermatology Outcome Measures (IDEOM) group 2016 New York meeting: meeting summary and data from the Psoriasis Working Group. J Drugs Dermatol. 2017;16(8):770–77.

36.

Strohal R, Prinz JC, Girolomoni G, Nast A. A patient-centred approach to biological treatment decision making for psoriasis: an expert consensus. J Eur Acad Dermatol Venereol. 2015;29(12):2390–8. https://doi.org/10.1111/jdv.13248.CrossRefPubMedPubMedCentral

37.

Blome C, Gosau R, Radtke MA, Reich K, Rustenbach SJ, Spehr C, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016;308(2):69–78. https://doi.org/10.1007/s00403-015-1613-8.CrossRefPubMed

38.

Okubo Y, Tsuruta D, Tang AC, et al. Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians. J Eur Acad Dermatol Venereol. 2018;32(4):606–14. https://doi.org/10.1111/jdv.14630.CrossRefPubMed

39.

Ahn CS, Culp L, Huang WW, Davis SA, Feldman SR. Adherence in dermatology. J Dermatolog Treat. 2016. https://doi.org/10.1080/09546634.2016.1181256.CrossRefPubMed

40.

Belinchon I, Rivera R, Blanch C, Comellas M, Lizan L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–67. https://doi.org/10.2147/PPA.S117006.CrossRefPubMedPubMedCentral

41.

Thorneloe RJ, Bundy C, Griffiths CE, Ashcroft DM, Cordingley L. Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis. Br J Dermatol. 2017;176(3):667–76. https://doi.org/10.1111/bjd.15086.CrossRefPubMed

42.

Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489–98. https://doi.org/10.1016/S0140-6736(15)00347-5.CrossRefPubMedPubMedCentral

43.

Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10. https://doi.org/10.1007/s00403-010-1080-1.CrossRefPubMed

44.

Armstrong AW, Siegel MP, Bagel J, et al. From the medical board of the national psoriasis foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2016. https://doi.org/10.1016/j.jaad.2016.10.017.CrossRefPubMed

45.

Gulliver W, Lynde C, Dutz JP, et al. Think beyond the skin: 2014 Canadian expert opinion paper on treating to target in plaque psoriasis. J Cutan Med Surg. 2015;19(1):22–7. https://doi.org/10.2310/7750.2014.13151.CrossRefPubMed

46.

Baker C, Mack A, Cooper A, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol. 2013;54(2):148–54. https://doi.org/10.1111/ajd.12014.CrossRefPubMed

47.

Duarte GV, Porto-Silva L. de Oliveira MD (2015) Epidemiology and treatment of psoriasis: a Brazilian perspective. Psoriasis (Auckl). 2015;5:55–64.

48.

Hernandez-Vasquez A, Molinari L, Larrea N, Ciapponi A. Psoriasis in Latin America and the Caribbean: a systematic review. J Eur Acad Dermatol Venereol. 2017;31(12):1991–8. https://doi.org/10.1111/jdv.14393.CrossRefPubMed

49.

Ministry of Health Malaysia. Clinical practice guidelines: management of Psoriasis vulgaris. Putrajaya: Malaysia Health Technology Assessment Section, Ministry of Health Malaysia; 2013.

50.

Elewski BE, Puig L, Mordin M, et al. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatolog Treat. 2017;28(6):492–99. https://doi.org/10.1080/09546634.2017.1294727.CrossRefPubMed

51.

Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (DLQI): further data. Dermatology. 2015;230(1):27–33. https://doi.org/10.1159/000365390.CrossRefPubMed

52.

Kimball A, Sundaram M, Mulani PM, Bao Y. Quality of life effects of psoriasis skin symptoms affecting different body regions. J Am Acad Dermatol; 2012;66(4)[Suppl 1]:AB202.

53.

Basra MK, Sue-Ho R, Finlay AY. The family dermatology life quality index: measuring the secondary impact of skin disease. Br J Dermatol. 2007;156(3):528–38. https://doi.org/10.1111/j.1365-2133.2006.07617.x.CrossRefPubMed

54.

Basra MK, Zammit AM, Kamudoni P, Eghlileb AM, Finlay AY, Salek MS. PFI-14(c): a rasch analysis refinement of the psoriasis family index. Dermatology. 2015;231(1):15–23. https://doi.org/10.1159/000379748.CrossRefPubMed

55.

Martinez-Garcia E, Arias-Santiago S, Valenzuela-Salas I, Garrido-Colmenero C, Garcia-Mellado V, Buendia-Eisman A. Quality of life in persons living with psoriasis patients. J Am Acad Dermatol. 2014;71(2):302–7. https://doi.org/10.1016/j.jaad.2014.03.039.CrossRefPubMed

56.

Golics CJ, Basra MK, Finlay AY, Salek S. The development and validation of the Family Reported Outcome Measure (FROM-16)(c) to assess the impact of disease on the partner or family member. Qual Life Res. 2014;23(1):317–26. https://doi.org/10.1007/s11136-013-0457-y.CrossRefPubMed

57.

Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(21):2102. https://doi.org/10.1056/NEJMc1610828.CrossRefPubMed

58.

Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–9. https://doi.org/10.1016/j.jaad.2015.05.013.CrossRefPubMed

59.

Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–86. https://doi.org/10.1111/bjd.14493.CrossRef

60.

Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus Ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551–60. https://doi.org/10.1056/NEJMoa1607017.CrossRef

61.

Papp K, Thaci D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930–9. https://doi.org/10.1111/bjd.13932.CrossRef

62.

Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17. https://doi.org/10.1016/j.jaad.2016.11.041.CrossRef

63.

Gordon KB, Armstrong AW, Menter MA, Wu JJ. Treating to target—a realistic goal in psoriasis? Semin Cutan Med Surg. 2018;37(2S):S44–7. https://doi.org/10.12788/j.sder.2018.010.CrossRefPubMed

64.

Feldman SR, Bushnell DM, Klekotka PA, et al. Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. J Dermatol Treat. 2016;27(3):224–7. https://doi.org/10.3109/09546634.2015.1093589.CrossRef

65.

Papp K, Menter A, Poulin Y, Gu Y, Sasso EH. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. J Eur Acad Dermatol Venereol. 2013;27(5):634–42. https://doi.org/10.1111/j.1468-3083.2012.04515.x.CrossRefPubMed

66.

Poulin YOM, Sheth P, Gu Y. Psoriasis patients required to discontinue adalimumab therapy have worsening in their quality of life out of proportion to worsening in the objective signs of disease: Subanalysis of REVEAL. J Am Acad Dermatol. 2012;66(4)[Suppl 1]:AB201. https://doi.org/10.1016/j.jaad.2011.11.841

67.

Warren RB, Smith CH, Yiu ZZ, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the british association of dermatologists biologic interventions register (BADBIR). J Invest Dermatol. 2015;135(11):2632–40. https://doi.org/10.1038/jid.2015.208.CrossRefPubMed

68.

Davila-Seijo P, Dauden E, Carretero G, et al. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. J Eur Acad Dermatol Venereol. 2016;30(11):1942–50. https://doi.org/10.1111/jdv.13682.CrossRefPubMed

69.

Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016. https://doi.org/10.1111/jdv.13611.CrossRefPubMedPubMedCentral

70.

Schaeverbeke T, Truchetet ME, Kostine M, Barnetche T, Bannwarth B, Richez C. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology (Oxford). 2016;55(2):210–20. https://doi.org/10.1093/rheumatology/kev277.CrossRef

71.

Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014;53(2):213–22. https://doi.org/10.1093/rheumatology/ket260.CrossRef

72.

Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244–52. https://doi.org/10.1111/bjd.13343.CrossRefPubMed

73.

Gyulai R, Bagot M, Griffiths CE, et al. Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. J Eur Acad Dermatol Venereol. 2015;29(2):224–31. https://doi.org/10.1111/jdv.12495.CrossRefPubMed

74.

Warren RB, Mrowietz U, von Kiedrowski R, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10068):528–37. https://doi.org/10.1016/S0140-6736(16)32127-4.CrossRefPubMed

75.

Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825–34.CrossRef

76.

Simpson JK, Wilson M, Ahmed AA, Mizara A, Clarke A, McBride SR. An exploratory study to investigate health-seeking behaviour in patients with psoriasis using framework analysis. Br J Dermatol. 2017. https://doi.org/10.1111/bjd.15307.CrossRefPubMedPubMedCentral

77.

Gottlieb AB, Greb JE, Goldminz AM. Psoriasis trends and practice gaps. Dermatol Clin. 2016;34(3):235–42. https://doi.org/10.1016/j.det.2016.03.004.CrossRefPubMed

78.

Kaushik SB, Lebwohl MG. CME part I psoriasis: which therapy for which patient psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2018. https://doi.org/10.1016/j.jaad.2018.06.057.CrossRefPubMed

79.

Kaushik SB, Lebwohl MG. CME part II psoriasis: which therapy for which patient focus on special populations and chronic infections. J Am Acad Dermatol. 2018. https://doi.org/10.1016/j.jaad.2018.06.056.CrossRefPubMed

80.

Boutayeb A, Boutayeb S. The burden of non communicable diseases in developing countries. Int J Equity Health. 2005;4(1):2. https://doi.org/10.1186/1475-9276-4-2.CrossRefPubMedPubMedCentral

81.

Boutayeb A. The double burden of communicable and non-communicable diseases in developing countries. Trans R Soc Trop Med Hyg. 2006;100(3):191–9. https://doi.org/10.1016/j.trstmh.2005.07.021.CrossRefPubMed

82.

DeCoster E, Alves de Medeiros A, et al. A multileveled approach in psoriasis assessment and follow-up: a proposal for a tailored guide for the dermatological practice. J Dermatolog Treat. 2016;27(4):298–310. https://doi.org/10.3109/09546634.2015.1117566.

83.

Hoffman MB, Hill D, Feldman SR. Current challenges and emerging drug delivery strategies for the treatment of psoriasis. Expert Opin Drug Deliv. 2016;13(10):1461–73. https://doi.org/10.1080/17425247.2016.1188801.CrossRefPubMed

Title: Clinical Goals and Barriers to Effective Psoriasis Care
Authors: Bruce E. Strober
Joelle M. van der Walt
April W. Armstrong
Marc Bourcier
Andre V. E. Carvalho
Edgardo Chouela
Arnon D. Cohen
Claudia de la Cruz
Charles N. Ellis
Andrew Y. Finlay
Alice B. Gottlieb
Johann E. Gudjonsson
Lars Iversen
C. Elise Kleyn
Craig L. Leonardi
Charles W. Lynde
Caitriona Ryan
Colin T. Theng
Fernando Valenzuela
Ronald Vender
Jashin J. Wu
Helen S. Young
Alexa B. Kimball
Publication date: 01-03-2019
Publisher: Springer Healthcare
Published in: Dermatology and Therapy / Issue 1/2019
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI: https://doi.org/10.1007/s13555-018-0279-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Clinical Goals and Barriers to Effective Psoriasis Care

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

A Simulation-Based Workshop to Improve Dermatologists’ Communication Skills: A Pilot for Continuing Medical Education

Efficacy and Safety of a Water-Based Head Lice Lotion: A Randomized, Controlled, Investigator-Blinded, Comparative, Bicentric Study

Evaluation of Antibiotic Treatment on the Duration of Hospitalization of Patients with Erysipelas and Bacterial Cellulitis

Self-Assessments of Standardized Scalp Massages for Androgenic Alopecia: Survey Results

A Summary of 2018 and What Lies Ahead for Dermatology and Therapy in 2019

A Case Report of Scrotal Rejuvenation: Laser Treatment of Angiokeratomas of the Scrotum

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page